Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.21
(2.56%)
CNY 3.21
(2.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 269.54 Million CNY | -7.25% |
| 2022 | 290.59 Million CNY | -12.24% |
| 2021 | 331.12 Million CNY | 9.95% |
| 2020 | 301.16 Million CNY | -63.67% |
| 2019 | 829.04 Million CNY | 2226.81% |
| 2018 | 35.63 Million CNY | -17.05% |
| 2017 | 42.95 Million CNY | -49.23% |
| 2016 | 84.59 Million CNY | 38.58% |
| 2015 | 61.04 Million CNY | 88.02% |
| 2014 | 32.46 Million CNY | 488.19% |
| 2013 | 5.52 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | -100.0% |
| 2010 | 16.07 Million CNY | -60.84% |
| 2009 | 41.05 Million CNY | 11.23% |
| 2008 | 36.91 Million CNY | -5.75% |
| 2007 | 39.16 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 58.8 Million CNY | -78.11% |
| 2024 Q1 | 268.61 Million CNY | -0.35% |
| 2024 Q3 | 56.79 Million CNY | -3.42% |
| 2023 Q3 | 287.17 Million CNY | 2.1% |
| 2023 Q2 | 281.28 Million CNY | -8.24% |
| 2023 Q1 | 306.52 Million CNY | 5.48% |
| 2023 Q4 | 269.54 Million CNY | -6.14% |
| 2023 FY | 269.54 Million CNY | -7.25% |
| 2022 FY | 290.59 Million CNY | -12.24% |
| 2022 Q3 | 304.62 Million CNY | -0.76% |
| 2022 Q4 | 290.59 Million CNY | -4.6% |
| 2022 Q1 | 337.93 Million CNY | 2.06% |
| 2022 Q2 | 306.96 Million CNY | -9.16% |
| 2021 Q4 | 331.12 Million CNY | 3.74% |
| 2021 FY | 331.12 Million CNY | 9.95% |
| 2021 Q1 | 298.33 Million CNY | -0.94% |
| 2021 Q2 | 312.48 Million CNY | 4.74% |
| 2021 Q3 | 319.17 Million CNY | 2.14% |
| 2020 Q4 | 301.16 Million CNY | -1.26% |
| 2020 Q2 | 233.3 Million CNY | -25.03% |
| 2020 Q1 | 311.19 Million CNY | -62.46% |
| 2020 FY | 301.16 Million CNY | -63.67% |
| 2020 Q3 | 305.01 Million CNY | 30.74% |
| 2019 Q3 | 843.97 Million CNY | 1.61% |
| 2019 Q2 | 830.56 Million CNY | 2.53% |
| 2019 FY | 829.04 Million CNY | 2226.81% |
| 2019 Q4 | 829.04 Million CNY | -1.77% |
| 2019 Q1 | 810.06 Million CNY | 2173.54% |
| 2018 FY | 35.63 Million CNY | -17.05% |
| 2018 Q1 | 37.58 Million CNY | -12.51% |
| 2018 Q2 | 42.58 Million CNY | 13.3% |
| 2018 Q3 | 38.18 Million CNY | -10.33% |
| 2018 Q4 | 35.63 Million CNY | -6.68% |
| 2017 Q1 | 83.41 Million CNY | -1.4% |
| 2017 Q4 | 42.95 Million CNY | -39.78% |
| 2017 Q3 | 71.33 Million CNY | -12.02% |
| 2017 Q2 | 81.07 Million CNY | -2.8% |
| 2017 FY | 42.95 Million CNY | -49.23% |
| 2016 Q2 | 39.39 Million CNY | -35.7% |
| 2016 Q1 | 61.26 Million CNY | 0.36% |
| 2016 FY | 84.59 Million CNY | 38.58% |
| 2016 Q4 | 84.59 Million CNY | 101.27% |
| 2016 Q3 | 42.03 Million CNY | 6.7% |
| 2015 Q1 | 31.31 Million CNY | -3.55% |
| 2015 FY | 61.04 Million CNY | 88.02% |
| 2015 Q4 | 61.04 Million CNY | -23.06% |
| 2015 Q3 | 79.34 Million CNY | -0.9% |
| 2015 Q2 | 80.07 Million CNY | 155.7% |
| 2014 Q1 | 18.12 Million CNY | 228.28% |
| 2014 FY | 32.46 Million CNY | 488.19% |
| 2014 Q4 | 32.46 Million CNY | -10.52% |
| 2014 Q3 | 36.28 Million CNY | -1.82% |
| 2014 Q2 | 36.95 Million CNY | 103.96% |
| 2013 Q4 | 5.52 Million CNY | 0.0% |
| 2013 FY | 5.52 Million CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | -100.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 FY | - CNY | -100.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q1 | 10.59 Million CNY | -34.13% |
| 2010 Q2 | 33.25 Million CNY | 0.0% |
| 2010 FY | 16.07 Million CNY | -60.84% |
| 2010 Q4 | 16.07 Million CNY | 0.0% |
| 2009 FY | 41.05 Million CNY | 11.23% |
| 2008 FY | 36.91 Million CNY | -5.75% |
| 2007 FY | 39.16 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 1.45 Billion CNY | 81.434% |
| Realcan Pharmaceutical Group Co., Ltd. | 262.1 Million CNY | -2.836% |